Corvus Pharmaceuticals (CRVS) Competitors $4.40 -0.10 (-2.22%) As of 02:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. AUPH, WVE, NAGE, MLYS, RCUS, SYRE, AKBA, CVAC, ELVN, and PAHCShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), CureVac (CVAC), Enliven Therapeutics (ELVN), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Aurinia Pharmaceuticals Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics CureVac Enliven Therapeutics Phibro Animal Health Aurinia Pharmaceuticals (NASDAQ:AUPH) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community prefer AUPH or CRVS? Aurinia Pharmaceuticals received 282 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 61.97% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAurinia PharmaceuticalsOutperform Votes57773.41% Underperform Votes20926.59% Corvus PharmaceuticalsOutperform Votes29561.97% Underperform Votes18138.03% Does the media refer more to AUPH or CRVS? In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 9 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Corvus Pharmaceuticals' score of 0.87 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corvus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AUPH or CRVS more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals-10.23% -4.41% -3.07% Corvus Pharmaceuticals N/A -70.71%-45.90% Do insiders & institutionals believe in AUPH or CRVS? 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable valuation & earnings, AUPH or CRVS? Corvus Pharmaceuticals has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$247.30M4.52-$78.02M$0.2829.54Corvus PharmaceuticalsN/AN/A-$27.03M-$0.98-4.49 Which has more risk & volatility, AUPH or CRVS? Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Do analysts prefer AUPH or CRVS? Aurinia Pharmaceuticals currently has a consensus price target of $11.50, indicating a potential upside of 39.06%. Corvus Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 240.91%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAurinia Pharmaceuticals beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.94M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-4.738.8727.2520.01Price / SalesN/A263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book5.576.617.124.70Net Income-$27.03M$144.20M$3.24B$248.05M7 Day Performance12.53%3.88%2.75%2.62%1 Month Performance8.64%11.26%9.00%6.32%1 Year Performance112.56%3.96%31.41%13.78% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.6642 of 5 stars$4.40-2.2%$15.00+240.9%+110.3%$299.94MN/A-4.7330News CoverageAnalyst RevisionAUPHAurinia Pharmaceuticals3.3362 of 5 stars$8.14-0.6%$11.50+41.3%+45.8%$1.10B$247.30M-54.26300Positive NewsAnalyst RevisionWVEWave Life Sciences4.4461 of 5 stars$7.05-2.4%$21.17+200.2%+16.0%$1.09B$104.94M-6.35240News CoveragePositive NewsAnalyst ForecastAnalyst RevisionNAGENiagen Bioscience1.4834 of 5 stars$13.43+3.7%$18.00+34.0%N/A$1.06B$107.93M79.00120News CoverageAnalyst ForecastMLYSMineralys Therapeutics3.0564 of 5 stars$16.19+0.4%$38.00+134.7%+19.7%$1.06BN/A-4.4528Positive NewsAnalyst ForecastRCUSArcus Biosciences2.5538 of 5 stars$9.86-1.1%$24.13+144.7%-41.9%$1.04B$141M-3.13500Options VolumeAnalyst RevisionSYRESpyre Therapeutics2.392 of 5 stars$17.16+1.1%$53.40+211.2%-52.6%$1.03B$890K-2.3073Positive NewsAKBAAkebia Therapeutics4.4668 of 5 stars$3.83-3.5%$6.75+76.2%+221.6%$1.01B$184.91M-16.65430News CoverageHigh Trading VolumeCVACCureVac4.4809 of 5 stars$4.48+1.6%$11.00+145.5%-4.2%$1.01B$523.70M8.15880Trending NewsOptions VolumeGap UpELVNEnliven Therapeutics2.4871 of 5 stars$20.34-1.9%$37.25+83.1%-10.9%$998.06MN/A-10.7150Insider TradePAHCPhibro Animal Health3.8792 of 5 stars$24.23+0.6%$20.00-17.5%+45.6%$982.14M$1.19B50.481,860Positive News Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives Wave Life Sciences Alternatives Niagen Bioscience Alternatives Mineralys Therapeutics Alternatives Arcus Biosciences Alternatives Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives CureVac Alternatives Enliven Therapeutics Alternatives Phibro Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts